General Research Laboratory

General Research Laboratory (GRL) is a Japanese biotechnology company dedicated to the discovery and development of novel antiviral therapeutics, with a primary focus on HIV/AIDS and emerging viral threats like COVID-19. The company was established to translate the pioneering research of Dr. Hiroaki Mitsuya, who is credited with discovering the first successful anti-HIV drugs and the protease inhibitor Darunavir. GRL utilizes advanced structure-based drug design to create small molecule inhibitors that target viral proteases, specifically aiming to overcome the challenge of multi-drug resistance. Their pipeline includes several potent protease inhibitors, such as GRL-142 for HIV and GRL-0617 for SARS-CoV-2. By collaborating with global pharmaceutical leaders like Janssen, GRL aims to bring next-generation antiviral treatments to patients worldwide.